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Abstract
The transition from transcription initiation to elongation at the HIV-1 promoter is controlled by 
Tat, which recruits P-TEFb to TAR RNA to phosphorylate RNA polymerase II. It has long been 
unclear why the HIV-1 promoter is incompetent for elongation. We report that P-TEFb is recruited 
to the promoter in a catalytically inactive state bound to the inhibitory 7SK snRNP, thereby 
preventing elongation. It also has long been believed that TAR functions to recruit Tat to the 
promoter, but we find that Tat is recruited to the DNA template before TAR is synthesized. We 
propose that TAR binds Tat and P-TEFb as it emerges on the nascent transcript, competitively 
displacing the inhibitory 7SK snRNP and activating the P-TEFb kinase. Recruitment of an 
inhibitory snRNP complex at an early stage in the transcription cycle provides a new paradigm for 
controlling gene expression with a non-coding RNA.
RNA polymerase II (Pol II) activity can be regulated at several steps of the transcription 
cycle, including pre-initiation, DNA melting, initiation, promoter clearance, and 
elongation1. One well-studied case of regulation at the elongation step involves the HIV-1 
Tat protein, which relieves a block to elongation at the viral promoter2–4 and functions after 
recruitment of the basal transcription machinery5. Without Tat, Pol II is stalled soon after 
initiation and is inefficiently converted to the processive form6,7, a step requiring the 
recruitment of positive transcription elongation factor b (P-TEFb) to a promoter-proximal 
RNA element (TAR) on the nascent HIV-1 pre-mRNA8. P-TEFb is composed of cyclinT1 
(CycT1) and Cdk98–10 and is used at many promoters, including HIV-1, to phosphorylate 
Ser2 residues in the C-terminal domain (CTD) of Pol II11–13, thereby converting a non-
phosphorylated form (Pol IIa) to a hyper-phosphorylated form (Pol IIo) that engages in 
productive elongation14–16
P-TEFb catalytic activity is tightly controlled in cells by switching the equilibrium between 
two states, an active P-TEFb form, which can be recruited to chromatin by interacting with 
Brd417,18, and an inactive ribonucleoprotein form containing the 7SK snRNP, composed of 
7SK snRNA, Hexim1, and Larp7/Pip7S, in addition to the CycT1 and Cdk9 subunits10,19. 
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Even though P-TEFb can be recruited to chromatin via Brd4, there is evidence that Tat can 
directly recruit P-TEFb to the HIV-1 promoter independently of Brd418. The inactive P-
TEFb form also can also associate with a methylphosphate capping enzyme (Mepce), whose 
activity stabilizes the 7SK snRNA20.
Here we report the unexpected findings that Tat assembles into a complex with P-TEFb in 
its inactive 7SK snRNP form, and that this complex is recruited to the HIV-1 promoter 
before transcription initiation, in a TAR-independent manner. Once transcription begins, the 
nascent TAR hairpin is synthesized and is required to displace the inhibitory 7SK snRNP 
complex and activate the P-TEFb kinase, which occurs when Tat and CycT1 bind to TAR. 
Recruitment of the inhibitory 7SK snRNP complex at an early stage of the viral transcription 
cycle explains why P-TEFb is inactive at the viral promoter in the absence of Tat and 
establishes a new way to control the switch between transcription initiation and elongation.
RESULTS
P-TEFb/7SK snRNP assembles into Pol II complexes and Tat stimulates Cdk9 activity in 
vitro
We recently showed that P-TEFb (CycT1:Cdk9) is found not only in the previously 
described small and large P-TEFb complexes8,10,17,18, but also in purified Pol II 
complexes along with Tat21, like the Cdk7 and Cdk8 kinases22. We now have found that 
CycT1 and Cdk9 assemble into Pol II complexes even without Tat, along with non-
phosphorylated Pol II (but not elongating Pol IIo), TBP, and splicing factors, and 
surprisingly, the 7SK snRNP (Hexim1, Larp7 and 7SK snRNA) (Fig. 1a). All 7SK snRNP 
components remained bound to Pol II complexes when purified further by gel filtration, 
yielding a single peak of 2–4 MDa (Fig. 1b), as previously reported22. P-TEFb 
immunoprecipitated from these Pol II complexes was catalytically inactive on a CTD 
substrate but, remarkably, the Cdk9 kinase was activated after incubating with GST-Tat 
(Fig. 1b), but not with a non-functional Tat mutant (data not shown). This result suggested 
that Tat may promote dissociation of the 7SK snRNP from P-TEFb preassembled with Pol 
II, as it does with the inactive complex in cells23,24. Indeed, the stimulation of P-TEFb 
catalytic activity correlates well with the displacement of Hexim1 and Larp7 from Pol II 
complexes, while CycT1 and Cdk9 remain bound (Fig. 1c).
Assembly of Tat and P-TEFb/7SK snRNP at the HIV-1 promoter in vivo
Given that Tat and P-TEFb/7SK snRNP associate with Pol II and that Tat remodels the 7SK 
snRNP complex, we next examined Tat, P-TEFb/7SK snRNP, and co-factor occupancy at 
the HIV-1 promoter by chromatin immunoprecipitation (ChIP), utilizing eight PCR primer 
pairs (Fig. 2a) in a stable reporter cell line, with or without transfected Flag-tagged Tat 
(Supplementary Fig. 1 online). This high-resolution ChIP protocol provides a reasonably 
comprehensive view of factor occupancy in and around the HIV-1 promoter (Fig. 2a,b), 
extending previous studies of co-factor recruitment5,25,26, and for the first time, permits us 
to locate Tat. The ChIP signal for Tat was undetectable in mock transfections, or in cells 
transfected with a non-functional Tat mutant (Supplementary Fig. 2), but showed a high 
signal-to-noise at specific regions when transfected with optimal levels of Tat (Fig. 2b). As 
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anticipated, Tat occupies the transcribed region where TAR is located (+103) but, 
remarkably, was present at almost equivalent levels in the core promoter (−75) (lower by a 
factor of 1.5). Tat also was seen in the downstream transcribing region, consistent with 
previous reports that Tat travels with the elongating Pol II27. High binding specificity is 
indicated by the absence of signal in the far upstream and downstream regions, −845 and 
+4490 respectively, and the relatively low signal at −352.
Other factors also show tight binding distributions. In the absence of Tat, the basal 
transcription factors Sp1 and TBP were recruited exclusively to the core promoter (−75, Fig. 
2b), where their binding sites are known to reside28,29 (Supplementary Fig. 3). Occupancy 
of both Sp1 and TBP was stimulated modestly (increased by a factor of 2 to 2.5) by Tat, 
consistent with its previously reported effects on basal factor recruitment5 and with our 
observed location of Tat in the same −75 region. Because very little Tat was observed in the 
upstream enhancer region (−352), a region also unnecessary for Tat activation in 
transcription reporter assays (Supplementary Fig. 3), it appears that Tat is recruited to and 
functions at the core promoter and downstream elements and not at the distal enhancer.
In the absence of Tat, both P-TEFb subunits (CycT1 and Cdk9) were found at moderate 
levels predominantly in the core promoter region (−75) (Fig. 2b). Interestingly, like P-TEFb, 
the 7SK snRNP components Hexim1 and Larp7 also were observed predominantly in the 
core promoter, consistent with their co-purification in Pol II complexes (Fig. 1a, b). Because 
Larp7 is an integral component of the 7SK snRNP, and because depletion of Larp7 leads to 
degradation of 7SK snRNA30, we infer that 7SK snRNA also is recruited to the HIV-1 
promoter (see below). Upon Tat activation, CycT1 and Cdk9 occupancy increased by a 
factor of 2 to 3 at −75 and ~11 at +103 (Fig. 2b), implying that Tat further enhances P-TEFb 
recruitment at or near the transcription start site (TSS), and also increased P-TEFb 
occupancy by a factor of 6 to 22 through the transcribing unit, as expected given that P-
TEFb also is associated with elongating Pol II complexes31–34. Interestingly, while 
occupancy of the P-TEFb subunits increases upon Tat activation, an especially large 
decrease in the 7SK snRNP components is observed concomitantly in the +103 region 
(lower by a factor of ~12 for Larp7 and ~15 for Hexim1) but not at the core promoter (lower 
by a factor of ~1.3 for Larp7 and ~2 for Hexim1). These results are consistent with a model 
in which Tat binding to the nascent RNA is coupled to the dissociation of 7SK snRNP and 
activation of the P-TEFb kinase (see below).
P-TEFb can be recruited to chromatin through interaction with Brd417,18, which is capable 
of stimulating HIV-1 transcription in a Tat-independent manner18. In our ChIP assays, Brd4 
was constitutively present throughout the entire promoter and transcribing region and its 
profile was unchanged by Tat (Fig. 2b), in agreement with reports suggesting that the 
interaction between Brd4 and P-TEFb is not essential for Tat activation18.
Previous observations that Tat and P-TEFb interact with Pol II and HIV-1 preinitiation 
complexes (PICs)31,32,34,35 raised the possibilities that they assemble with a promoter-
paused Pol II, like some pre-mRNA processing factors36, and may not be recruited to the 
HIV-1 promoter directly through TAR recognition. Therefore, we analyzed total Pol II and 
CTD phospho-isoforms by ChIP (Fig. 2b). In the absence of Tat, total Pol II was localized 
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almost exclusively to the core promoter region (−75), and its occupancy rose by a factor of 
~2 upon Tat activation and by a factor of 8 to 24 throughout the transcribing region (Fig. 
2b). No Pol II was detected at the upstream enhancer region (−352), suggesting that 
chromatin looping between enhancer elements and the core promoter is not a major feature 
of Tat activation. Using Pol II CTD-specific antibodies to phosphorylated Ser5 (initiating) or 
Ser2 (elongating) Pol II, we observed exclusively the S5P-CTD form, but not the S2P-CTD, 
at the core promoter without Tat (Fig. 2b). Upon Tat activation, the level of S5P-CTD at the 
promoter increased by a factor of 5 to 6, suggesting that preloaded Pol II is not completely 
phosphorylated on Ser5-CTD residues before Tat activation, in agreement with a role of Tat 
in enhancing Ser5 phosphorylation in reconstituted transcription complexes in vitro33. The 
levels of both the S5P-CTD and S2P-CTD forms increased drastically (by a factor of 10 to 
100) throughout the transcribing unit, coincident with enhanced recruitment of P-TEFb to 
the promoter and release of the 7SK snRNP (Fig. 2b). The patterns of Pol II accumulation at 
the core promoter are consistent with a paused Pol II model7, where Pol II pauses near the 
promoter before TAR is fully transcribed6 and allows Tat to operate at post-initiation steps.
The association of RNA-binding proteins with DNA observed in ChIP assays sometimes 
relies on an RNA bridge37. Thus, we next performed ChIP experiments on RNase treated 
extracts (Fig. 2c) to determine if Tat and P-TEFb/7SK snRNP recruitment to the promoter 
depend on RNA (TAR or other RNAs). RNase treatment reduced Tat occupancy at the core 
promoter (−75) by a factor of ~2.5 but much more dramatically where TAR is positioned 
(+103) (lower by a factor of ~18) (Fig. 2c), likely reflecting loss of binding to the nascent 
TAR, while Sp1, TBP, Brd4, and Pol II occupancy were nearly unchanged (compare Fig. 2b 
to 2c). In marked contrast, CycT1, Cdk9, Hexim1, and Larp7 occupancy were drastically 
reduced by RNase treatment (lower by a factor of 2 to 16), suggesting that all may assemble 
as part of the entire 7SK snRNP complex. Unexpectedly, the RNAse treatment caused only 
a small reduction in the levels of S2P-CTD Pol II throughout the transcribing region despite 
the nearly total loss of CycT1 and Cdk9, suggesting that P-TEFb may still somehow 
associate with elongating Pol II in a manner that is affected by RNA (Fig. 2c). The Tat AD 
alone, lacking the RNA-binding domain, also was found at the core promoter (lower by a 
factor of 3 compared to Tat occupancy), and even in the absence of TAR (Supplementary 
Fig. 4), suggesting that Tat can assemble at the promoter through protein-protein 
interactions alone, although full occupancy requires protein-RNA contacts as well.
Recruitment of Tat and P-TEFb/7SK snRNP to the HIV-1 promoter does not require TAR
Because we observed Tat and P-TEFb/7SK snRNP complexes in regions of the HIV-1 
promoter upstream of the TSS, we wished to determine if TAR was necessary for their 
recruitment. We constructed a stable reporter cell line containing a TAR deletion and 
monitored factor occupancy with or without transfected Flag-tagged Tat (Fig. 2d). The 
results are particularly enlightening. First, Tat was still loaded at the promoter region (−75), 
showing a reduction in occupancy by a factor of only 2 when compared with TAR, whereas 
occupancy at +103 was virtually lost (lower by a factor of ~27). Second, CycT1, Cdk9, 
Hexim1, and Larp7, along with the basal transcription factors Sp1 and TBP, all were still 
loaded at the core promoter (−75) without TAR (compare Fig. 2d to 2b), demonstrating that 
TAR is not simply a binding site for Tat:P-TEFb recruitment. Third, Hexim1 and Larp7 
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were no longer displaced at +103 upon Tat activation, suggesting that the interaction of 
Tat:P-TEFb with TAR at the viral promoter is required to eject these subunits and 
presumably activate Cdk9. Finally, CycT1 and Cdk9 were no longer found throughout the 
transcribing region, nor was Pol II CTD Ser2 phosphorylation, providing compelling 
evidence that Hexim1 and Larp7 are not displaced from the viral promoter without TAR, 
and thus Cdk9 is not activated (Fig. 2d).
Tat assembles with 7SK snRNP in vivo
Previous studies have shown that Tat releases Hexim1 from inactive P-TEFb/7SK snRNP 
complexes23,24,30, and may do so in part by binding to a stem-loop near the 5’ end of 7SK 
snRNA where Hexim1 also binds30,38, thus competing with Hexim1 for CycT1-binding, as 
previously shown in vitro39. Given that Tat and 7SK snRNP, including Hexim1, are 
recruited to the HIV-1 promoter, we wished to further assess which interactions occur 
between Tat and the 7SK snRNP prior to promoter binding. We performed standard 
immunoprecipitation experiments with Flag-tagged Tat expressed stably in a 293 cell line, 
and also performed crosslinking conditions similar to those used for ChIP to trap potentially 
less stable or transient complexes37 with P-TEFb/7SK snRNP (Fig. 3). In the absence of 
crosslinking, CycT1, Cdk9, and Larp7 were detected along with Tat by Western blot and 
7SK snRNA by RT-PCR (Fig. 3, lane 4). Interestingly, in the formaldehyde-crosslinked 
sample, we observed the same components but in addition also found Hexim1 and about 7-
fold more 7SK snRNA, but no detectable U6 snRNA (Fig. 3, lane 5). No bound proteins 
were observed in control 293 cells not expressing Tat (Fig. 3, lane 6), and the crosslinking 
step did not affect the levels of input protein (Fig. 3, lanes 1–3). These results suggest that 
Tat and P-TEFb/7SK snRNP may form pre-assembled complexes before being recruited to 
the HIV-1 promoter.
Determinants for P-TEFb/7SK snRNP recruitment to the HIV-1 promoter
To provide direct evidence that P-TEFb/7SK snRNP complexes occupy the HIV-1 
promoter, we purified transcription PICs using biotinylated templates and streptavidin-
coated magnetic beads (Fig. 4a, top panel). Indeed, all components of the inactive P-TEFb 
complex were associated with the HIV-1 template, along with basal transcription factors 
(Sp1 and TBP), but not with a control promoterless template (Fig. 4a, bottom panel). The 
activity of the purified HIV-1 PICs was measured by in vitro transcription and primer 
extension and yielded the expected transcription product (Tp), which was inhibited by α-
amanitin (Fig. 4a, bottom panel), confirming that the purified PICs were competent for Pol 
II transcription.
The ChIP occupancy profile of Tat, basal transcription factors, and P-TEFb/7SK snRNP 
components (Fig. 2) indicated that the core promoter region is important for their 
recruitment. To test whether the core promoter is sufficient for transcription complex 
assembly in vitro and transcription activation, we synthesized a minimal template containing 
the Sp1, TATA, initiator, and TAR elements (base pairs −105 to +120) but lacking the 5’ 
enhancer region (Core HIV-1, Fig. 4b). Indeed, PIC assembly with the core template was 
identical to the full-length promoter (Fig. 4b), as was Tat activation in transcription reporter 
assays (Supplementary Fig. 3). Deleting the Sp1 or TATA elements reduced or eliminated 
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all interactions, basal transcription, and Tat activation (Fig 4b, Supplementary Fig. 3), 
suggesting that the basal machinery, Sp1 as suggested previously29,40,41, and P-TEFb/7SK 
snRNP, all contribute to forming a Tat-responsive complex.
We further assessed the in vivo relevance of Sp1 to Tat assembly at the promoter by 
depleting Sp1 with RNAi and monitoring factor occupancy by ChIP. Sp1 occupancy at the 
HIV-1 promoter decreased by a factor of ~8 (Fig. 4c) and Tat activity in transcription 
reporter assays decreased by a factor of ~10 (Supplementary Fig. 5). Furthermore, Sp1 
knockdown almost completely eliminated Tat occupancy at the promoter, strongly decreased 
CycT1 and Hexim1 occupancy, and reduced the levels of Pol II CTD Ser2 phosphorylation 
(Fig. 4c), suggesting that Sp1 may participate in P-TEFb/7SK snRNP interactions at the 
viral promoter in vivo. Indeed, previous data suggest that Sp1 and P-TEFb interact in vivo 
and that the interaction activates HIV-1 transcription29,41,42.
DISCUSSION
Current models of HIV-1 transcription activation propose that Tat and P-TEFb are recruited 
to the promoter by binding to TAR on the nascent transcript. However, here we provide 
evidence that Tat and P-TEFb, in complex with the inhibitory 7SK snRNP, are loaded into 
HIV-1 PICs prior to transcription initiation and in the absence of TAR (Figs. 2 and 4). 
Further, we provide evidence that Tat can displace the 7SK snRNP to activate the Cdk9 
kinase (Fig. 1), consistent with previous reports that Tat releases Hexim1 from the large and 
inactive P-TEFb complexes23,24,30, and importantly, that this activation step occurs as 
TAR emerges on the transcript (Fig. 2) from a promoter-paused Pol II7. These results lead to 
the following two-step model for Tat activation (Fig. 5a): First, the catalytically inactive P-
TEFb/7SK snRNP complex is recruited to the promoter with Tat, most likely as a pre-
assembled complex (Fig. 3) and through interactions with Sp1 or other basal transcription 
factors, and remains bound in promoter-paused transcription complexes (Figs. 4 and 5a). 
Second, the inhibitory 7SK snRNP is released by competitive binding of the Tat:P-TEFb 
complex to TAR as it is transcribed, thereby activating Cdk9 and Pol II CTD 
phosphorylation (Fig. 5a). Importantly, Tat and P-TEFb/7SK snRNP complexes are 
recruited to PICs even in a TAR-deleted promoter (Fig. 2d), and in the absence of 
transcription (Fig. 4a), providing direct evidence that TAR does not function solely as a 
recruitment site for Tat and CycT1. Even though Tat assembles into PICs in the TAR-
deleted promoter, it does not activate Cdk9 and therefore the transcription complexes remain 
incompetent for elongation (Fig. 5b). In this revised model, TAR provides the essential 
function of transferring Tat and CycT1 to the nascent RNA, displacing the inhibitory 7SK 
snRNP in the process (Fig. 5a).
Several previous observations are consistent with this basic model of Tat activation: (i) P-
TEFb has been found in HIV-1 PICs in the absence of Tat and remains associated with 
productive elongation complexes31–34,43; (ii) Tat has been found in complexes with Pol II 
and HIV-1 PICs prior to synthesis of TAR21,35,44; and Hexim1 over-expression inhibits 
Tat activation45. The finding that Tat is present in PICs is consistent with the observation 
that it stimulates HIV-1 transcription complex assembly5, perhaps by enhancing P-TEFb 
recruitment or stabilizing PICs at the promoter (Figs. 2 and 4).
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In our model, P-TEFb is transferred to the nascent RNA co-transcriptionally soon after TAR 
is synthesized, allowing Tat and CycT1 to bind and competitively displace the 7SK snRNP. 
We envision that the role of TAR in ejecting the inhibitory 7SK snRNP subunits ensures that 
Cdk9 becomes activated on the nascent RNA and effectively times the switch between 
initiation and elongation. The precise nature of the nascent RNA appears unimportant for 
triggering Cdk9 activation, as the Tat-TAR interaction can be functionally replaced by 
heterologous RNA-protein interactions when the Tat activation domain is fused to the 
cognate RNA-binding domain46–49. Therefore, it is not TAR per se but rather the protein-
RNA binding step that dissociates 7SK snRNP and activates the P-TEFb kinase. In contrast, 
the Tat activation domain is indispensable for activation, consistent with the observation that 
it is the minimal domain required to displace Hexim1 from P-TEFb by competing for the 
same interaction surface on CycT1, and to activate Cdk910,23,39. Even when the Tat 
activation domain alone is recruited to the HIV-1 promoter (Supplementary Fig. 4), it does 
not activate transcription, consistent with the idea that Tat does not dissociate the 7SK 
snRNP without the TAR binding step (Figs. 2 and 5). In agreement with the proposed co-
transcriptional role for TAR, our ChIP data show that Tat cannot displace Hexim1 from the 
7SK snRNP or increase Pol II Ser2 CTD-phosphorylation when TAR is deleted (Fig. 2b,d), 
although recombinant Tat can do so at high concentrations in vitro in the absence of 
template DNA or TAR (Fig. 1c). We speculate that an additional step in which Tat does not 
activate the P-TEFb kinase until TAR is synthesized is not recapitulated under these in vitro 
conditions.
It is interesting that both Tat and Hexim1 are able to bind to a 5’ region of 7SK snRNA in 
vitro30,38, that Hexim1 possesses an arginine-rich similar to the RNA-binding of Tat10, and 
that both compete for the same interaction surface on CycT123,39,45. These results provide 
evidence for molecular mimicry between the viral and host protein-RNA complexes (Tat-
TAR and Hexim1-7SK snRNA) and suggest a competition model in which Tat takes the 
place of Hexim1 during the formation of transcription elongation complexes (Fig. 5), 
consistent with the observation that Tat displaces Hexim1 from the 7SK snRNP. Our 
findings also help resolve two apparent paradoxes. First, drugs that impair Pol II activity, 
like actinomycin D, activate the HIV-1 promoter50; and intriguingly it stimulates the release 
of Hexim1 from the HIV-1 promoter mimicking Tat, albeit not as efficiently 
(Supplementary Fig. 6). Second, drugs that reduce the levels of the inactive P-TEFb 
complex correspondingly reduce HIV-1 replication rates51.
There are striking similarities between Tat:P-TEFb loading at the HIV-1 promoter and 
transfer to the nascent pre-mRNA with co-transcriptional processes in which some pre-
mRNA processing factors, such as the capping machinery and splicing factors, initially are 
loaded on a promoter-paused Pol II complex and later transferred to the pre-mRNA36,52,53. 
The proposed co-transcriptional mechanism helps solve a longstanding puzzle as to why 
HIV-1 evolved the use of an RNA site, in this case TAR, to regulate transcription. In our 
model, TAR does not function like a simple enhancer to recruit Tat to the nascent RNA, but 
rather allows an RNA-binding step to time the transition into productive elongation. This 
resembles the stimulatory effect of splicing factors on transcription elongation54. It remains 
to be determined if cellular promoters regulate P-TEFb activity by related mechanisms, but 
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it is interesting that the 3’ UTR of HIC mRNA activates HIV-1 transcription elongation in a 
P-TEFb-dependent manner by displacing 7SK snRNA through a yet uncovered 
mechanism55. It is further possible that inactive P-TEFb complexes are assembled at 
cellular promoters and become activated by mechanisms that do not require a TAR-like 
RNA element. Indeed, Gal4-Tat and Gal4-P-TEFb fusions can activate transcription of an 
HIV-1 promoter containing several Gal4 DNA-binding sites, although multiple sites are 
required and activation is weaker than with TAR (5,56; D’Orso, unpublished data), implying 
that the normal pathway of activation may not be fully recapitulated by artificial tethering of 
transcription factors or co-activators. Similarly, recruiting a Gal4-P-TEFb fusion to the 
hsp70 promoter in Drosophila activates transcription in the absence of heat shock, but to a 
lower level than when activated by heat shock factor-157.
HIV-1 transcription activation by Tat provides yet another example in which a virus exploits 
a cellular control mechanism, in this case the coupling of transcription with pre-mRNA 
processing53 through the use of a regulatory non-coding RNA. It will be interesting to test if 
acetylation of the Tat activation domain, which enhances formation of the elongation 
complex on TAR49, facilitates Tat-7SK snRNP assembly or the eviction of 7SK snRNP 
from the HIV-1 promoter. Understanding how Tat-7SK snRNP assembly/disassembly may 
be coordinated with the activity of the 7SK snRNA capping enzyme Mepce20,30, with the 
activities of other elongation factors, such as DSIF and NELF, or with histone modifications 
at the HIV-1 promoter6,26 also requires further investigation. Finally, as mentioned above, 
it seems unlikely that the assembly of inactive P-TEFb/7SK snRNP complexes at the HIV-1 
promoter is unique, raising the question of whether other cellular genes utilize similar 
mechanisms to control the switch between initiation and elongation.
METHODS
HIV-1 LTR reporter HeLa cell lines
To generate cell lines with an integrated reporter for ChIP analyses, we transfected HeLa 
cells with Ssp1-linearized pcDNA3.1 bearing the HIV-1 LTR reporters using 
Lipofectamine2000. We selected clones for more than four weeks in DMEM–10% FBS with 
750 µg/ml of geneticin. We analyzed forty clones transfected with the wild-type reporter by 
transcription activation assays with HIV-1 Tat and selected several with reproducible 
activity levels. For ChIP analyses, we chose a single active clone containing 14 integrants 
and responsive to Tat. To generate the HIV-1 LTRΔTARFFL-containing cell line, we 
selected 32 clones and chose one containing 15 integrants that was responsive to TNF-µ for 
the ChIP assays21. The number of integration sites was determined by quantitative PCR21 
with PCR primers shown in Supplementary Methods online (Supplementary Table 1 online).
ChIP
We transfected reporter cell lines with Tat plasmids by calcium phosphate, incubated for 36 
hr, and washed in PBS. We crosslinked the chromatin with 1% formaldehyde for 5–15 min 
at room temperature and stopped the reaction by adding glycine (to 150 mM). We washed 
cells with PBS, harvested in RIPA buffer, and sonicated samples to generate ~150–bp DNA 
fragments. For immunoprecipitation, we pre-cleared 1 mg of protein extract for 1 hr with 50 
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µl of protein A- or G-dynabeads before adding 2–10 µg of antibody (Supplementary Table 
2) to a fresh tube containing dynabeads. We incubated reaction mixtures overnight at 4°C 
with 50 µl of protein A/G-dynabeads pre-blocked with 0.5 mg ml−1 bovine serum albumin 
and 0.1 mg ml−1 of salmon sperm DNA. We washed the beads twice with RIPA buffer, four 
times with ChIP wash buffer (100 mM Tris-HCl pH 8.5, 500 mM LiCl, 1% (v/v) Nonidet 
P-40, 1% (w/v) deoxycholic acid), twice with RIPA buffer, and twice with 1× Tris-EDTA. 
We eluted immunocomplexes for 15 min at 65°C with 1% (w/v) SDS, and reversed the 
crosslinking by adjusting the solution to 200 mM NaCl and incubating for 16 hr at 65°C. We 
used a fraction of the DNA as the template in PCR reactions, which were performed in the 
exponential range of amplification (24 to 32 cycles, depending on the primer combination 
and antibody used). We electrophoresed amplification products (~70 bp) in 2.5% (w/v) 
agarose gels and visualized with ethidium bromide. PCR primer sequences are shown in 
Supplementary Table 1. Quantification of PCR products was performed with Scion 
Image1.63 software using known input DNA standards.
In vivo RNA Immunoprecipitation (RIP)
We crosslinked cells with formaldehyde to stably trap RNA-protein complexes formed in 
vivo37. Briefly, we crosslinked 293 T-Rex Tat cells in 0.1% (v/v) formaldehyde for 8 min at 
room temperature; washed and resuspended cell pellets in 50 mM Tris (pH 7.4), 1% (v/v) 
NP-40, 0.5% (w/v) sodium deoxycholate, 0.05% (w/v) SDS, 2 mM MgCl2, and 150 mM 
NaCl; and sonicated three times for 20 sec each on a Branson Sonifier 450 with microtip. 
We incubated extracts for 3 hr at 4°C with protein G dynabeads pre-bound with mouse anti-
Flag or mouse anti-GFP antibody as controls. We washed bound samples four times for 10 
min in binding buffer supplemented with 1 M urea and 0.5 M NaCl and then resuspended in 
50 mM Tris pH 6.3, 5 mM EDTA, 1% (w/v) SDS, and 10 mM DTT. We reversed crosslinks 
by heating for 45 min at 70°C, purified RNA with TRIzol reagent, and performed first-
strand cDNA synthesis using random decamers. We detected 7SK and U6 snRNAs 
(Supplementary Table 3) by RT-PCR.
RNAi
For Sp1 knockdown, we plated HeLa cells to a density of 5×105 cells per well in 6-well 
plates and analyzed by Western blot 72 hr after transfecting Sp1 siRNA (sc-29487) or 
scrambled siRNA (sc-37007) (Santa Cruz). For RNAi-ChIP, we plated cells in 15 cm2 
dishes, transfected with the siRNA for 72 hr, and then re-transfected with a Tat-Flag (or 
empty vector) for 36 hr before harvesting for ChIP assays.
Purification of Pol II complexes
We used a TFIIS affinity resin to purify Pol II22,58. To prepare the resin, we lysed E. coli 
BL21 DE3 cells expressing GST or GST-TFIIS(N) (a TFIIS N terminal fragment22) by 
sonication in TBS buffer containing 150 mM NaCl and protease inhibitors (2 mM PMSF 
and 1 mM EDTA) on ice. We clarified and treated supernatants with 1% (v/v) Triton X-100 
for 10 min, centrifuged, and bound to a glutathione-agarose resin. We prepared HeLa whole 
cell extracts (WCE) as described22, and purified Pol II complexes eluted from the TFIIS 
resin further by gel filtration on a Sepharose CL-2B column in 20 mM Tris-HCl pH 7.9, 0.1 
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mM DTT, 0.1 mM EDTA, 20% glycerol, and 150 mM NaCl. We analyzed composition by 
Western blotting with a panel of antibodies and by RT-PCR of TRIZol-purified RNAs to 
detect 7SK RNA with primers shown in Supplementary Table 3. We immunoprecipitated P-
TEFb from the Pol II preparation using an anti-Cdk9 antibody and used it for two 
experiments: kinase activity (Fig. 1b) and disassembly of 7SK snRNP in vitro (Fig. 1c). To 
measure CTD kinase activity, we incubated 50 ng of GST-CTD and 100 µM ATP in the 
absence or presence of GST-Tat (100 ng) in 50 mM Tris-HCl pH 7.5, 1.5 mM DTT, 5 mM 
MnCl2, and 4 mM MgCl2 for 60 min at 30°C. We detected phosphorylated GST-CTD (CTD 
IIo form) by Western blotting with a Ser2P-CTD antibody. GST-Tat (residues 1–72) was 
expressed from a pGEX2T vector and purified on a glutathione-agarose column. To test the 
role of GST-Tat on the integrity of the 7SK snRNP complex in vitro, we purified Pol II 
complexes on a GST-TFIIS column, incubated for 30 min with GST or GST-Tat, 
immunoprecipitated Cdk9 as in Fig. 1b, and analyzed bound factors by Western blot. To 
monitor transcription, we prepared nuclear extracts49 and performed transcription reactions 
using immobilized linear templates and primer extension.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Inactive P-TEFb assembles into Pol II complexes and Tat activates its catalytic activity. (a) 
Partial composition of Pol II complexes purified on a TFIIS affinity resin22 was assessed by 
comparing Western blots of proteins and levels of 7SK snRNA eluted from a GST-TFIIS 
column to those from HeLa whole cell extracts (WCE) and a GST control column. The 
TFIIS used was an N-terminal fragment that possesses the same activity as full-length 
TFIIS22. The purified coomassie-stained recombinant GST and GST-TFIIS proteins used 
for the columns are shown on the left. The arrow indicates the position of full-length CycT1. 
(b) GST-TFIIS eluted complexes were loaded onto a Sepharose CL-2B gel filtration column 
and the single eluted peak was immunoprecipitated (IP) by either anti-Cdk9 or mock 
(normal rabbit IgG) antibodies. Both precipitates, either incubated or not with purified GST-
Tat, were used in kinase assays using a GST-CTD substrate and analyzed by Western blot 
with the H5 antibody, which recognizes Pol IIo. (c) Pol II complexes were purified on a 
TFIIS affinity resin, incubated with GST or GST-Tat in vitro, immunoprecipitated with anti-
Cdk9 antibody, and the presence of P-TEFb (CycT1 and Cdk9) and 7SK snRNP (Hexim1 
and Larp7) was monitored by Western blot.
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Figure 2. 
Distribution of Tat and cofactors at the HIV-1 promoter and dependence on TAR. (a) 
Schematic of the HIV-1 LTR promoter-luciferase (FFL) reporter integrated into a HeLa cell 
line, showing the locations of the upstream region (−845), enhancer elements (−352), core 
promoter containing Sp1 and TATA-boxes (−75), transcription start site (TSS; +1), TAR 
element, FFL coding region, stop codon, and polyadenylation signal (p(A)). The locations of 
eight amplicons used in PCR quantification of ChIP-enriched DNA are shown. Numbers 
indicate the positions of the central base pair of each amplicon relative to the TSS. (b) ChIP 
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assays were performed with protein extracts from the reporter cell line 48 hr after a mock 
(grey bars) or Flag-tagged Tat transfection (black bars) using the antibodies indicated. 
Values represent the percentage of input DNA immunoprecipitated and are the average of 
four independent PCRs from two separate immunoprecipitations from two independent cell 
cultures. All standard deviations are <15%. (c) ChIP assays were performed as in panel b but 
using extracts pre-treated with RNase A. (d) ChIP assays were performed with protein 
extracts obtained from a HeLa HIV-1 LTRΔTAR-FFL cell line 48 hr after a mock (grey 
bars) or Flag-tagged Tat transfection (black bars) using the antibodies indicated.
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Figure 3. 
Tat assembles with the 7SK snRNP in vivo. RNA immunoprecipitation (RIP) was performed 
using antibodies to Flag-tagged Tat. Western blots (upper panels) indicate that components 
of P-TEFb (CycT1 and Cdk9) and 7SK snRNP (Larp7 and Hexim1) form a complex with 
Tat. The two lower panels utilized RT-PCR to detect 7SK and U6 snRNAs.
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Figure 4. 
7SK snRNP and Tat recruitment to HIV-1 PICs are Sp1-dependent. (a) Promoterless and 
full-length LTR templates were immobilized to streptavidin-coated magnetic beads through 
a biotin moiety at the 5’ end, and a NotI site was used to cleave the promoter and elute 
proteins from the beads, which were then analyzed by Western blot. The activity of the 
purified HIV-1 PICs was measured by in vitro transcription and primer extension and 
yielded the expected transcription product (Tp), and was inhibited by α-amanitin treatment. 
(b) The immobilized full-length HIV-1 LTR, core, and mutant templates shown were 
incubated with HeLa nuclear extracts and washed, and proteins were eluted with NotI and 
identified by Western blot. In vitro transcription of the PICs produced the correct Tp. (c) 
HeLa HIV-1 LTR reporter cells were transfected with a control scrambled siRNA or a 
siRNA against Sp1, resulting in >80% depletion of Sp1 and decrease in reporter activity 
(Supplementary Fig. 5), and ChIP assays were performed using the antibodies indicated. 
Values represent the percentage of input DNA immunoprecipitated and are the average of 
four independent PCRs from two separate immunoprecipitations from two independent cell 
cultures. All standard deviations are <15%
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Figure 5. 
Proposed model of HIV-1 transcription activation by Tat. (a) Tat assembles into complexes 
with P-TEFb (CycT1 and Cdk9) and the 7SK snRNP (Hexim1, Larp7, and 7SK snRNA). 
This Tat-7SK snRNP complex is recruited to HIV-1 PICs containing the Pol IIa form and 
the basal transcription machinery (e.g. Sp1, TBP), among other possible promoter-specific 
factors, and remains bound in the paused state (Paused complex). As transcription proceeds 
and TAR is synthesized, Tat facilitates the transfer of P-TEFb to the nascent RNA site. We 
propose that this Tat-TAR binding event competitively displaces 7SK snRNP and activates 
Cdk9 to phosphorylate Ser2 residues in the CTD (P) and assemble competent transcription 
elongation complexes containing a Pol IIo form. Hexim1 may dissociate from Larp7/7SK 
snRNA complexes, as it is not stably bound30, and may be replaced by hnRNP proteins in a 
transcription-dependent manner59,60. (b) In the absence of TAR, Tat and P-TEFb do not 
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transfer to the nascent RNA and evict the 7SK snRNP, preventing Ser2-CTD 
phosphorylation (P) and formation of elongation complexes.
D’Orso and Frankel Page 20
Nat Struct Mol Biol. Author manuscript; available in PMC 2011 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
